-
Authors of the Standards of Care in Diabetes—2026 will share insights on annual updates
This Saturday symposium, featuring Anne Peters, MD, Elizabeth Ann Beverly, PhD, Emily D. Szmuilowicz, MD, MS, and others, will cover chapters on diabetes technology, facilitating positive health behaviors, pharmacological approaches to glycemic management, cardiovascular disease and risk management, pregnancy, and diabetes in children and adolescents.
-
Session to provide updates on MASLD, lipoprotein biology, and CV risk
Panelists will discuss an underexplored nexus of metabolic dysfunction in diabetes on the final day of the 2026 Scientific Sessions. Scott Summers, PhD, will explore the role of ceramides in metabolic dysfunction-associated steatotic liver disease and cardiovascular risk. Other topics include cholesterol, clot lysis, and thrombosis.
-
Hot topics in nutrition for 2026: menopause, ultraprocessed foods, misinformation, and care delivery for immigrant populations
Presenters, including Hillary Wright, MEd, RDN, LDN, will discuss trending topics in nutrition and how food choices and other factors affect individuals living with diabetes across different ages and ethnicities.
-
Researchers to reveal trial results for dual agonism in type 1 diabetes
Experts, including Klara Klein, MD, PhD, will discuss the possible benefits of a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA) for people living with type 1 diabetes.
-
Symposium to analyze amylin as novel therapy for diabetes and weight loss
W. Timothy Garvey, MD, and other researchers will share new insights from trials, such as REDEFINE, exploring long-acting amylin analogs as mono-agonists and in combination with agonists for other hormone receptors.
-
Experts to review the benefits and challenges of GLP-1 RAs beyond diabetes and obesity
Investigators will give an overview of new therapies coming into the market. Panelist Donna Ryan, MD, will discuss clinical trials for incretin-based therapies.
-
Debate to focus on BMI and definitions of obesity
Body mass index (BMI) is one of the most controversial topics in the assessment of obesity today. Session Chair Robert Kushner, MD, previews a debate on whether this metric should be the primary tool in defining obesity.
-
Panel discussion to track diabetes across diverse populations in the U.S.
Jithin Sam Varghese, PhD, MTech, and other panelists will delve into the epidemiology of diabetes, social roadblocks, and variations in health outcomes across the country amid changing national demographics.
-
Experts to reveal results of retatrutide trials TRANSCEND-T2D-1 and TRIUMPH-1
Jonathan Campbell, PhD, and other panelists will share new data and address how this triple-hormone receptor agonist may unlock the next frontier of treatment for obesity and type 2 diabetes.
-
Primary results for SOLSTICE and VISTA to be shared for the first time
Vanita R. Aroda, MD, and Melanie Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSci, will review the latest data for a novel oral glucagon-like peptide-1 receptor agonist in people living with with type 2 diabetes or overweight or obesity.